ATI RN
ATI Pharmacology Proctored Exam 2023 Quizlet
1. A client with chronic renal disease is receiving therapy with epoetin alfa. Which of the following laboratory results should the nurse review for an indication of a therapeutic effect of the medication?
- A. The leukocyte count
- B. The platelet count
- C. The hematocrit (Hct)
- D. The erythrocyte sedimentation rate (ESR)
Correct answer: C
Rationale: The correct answer is C: The hematocrit (Hct). Monitoring the hematocrit is essential to assess the therapeutic effect of epoetin alfa because this medication stimulates red blood cell production in clients with chronic renal disease. The leukocyte count (choice A) and platelet count (choice B) are not directly affected by epoetin alfa therapy. The erythrocyte sedimentation rate (ESR) (choice D) is a non-specific marker of inflammation and is not used to monitor the therapeutic effect of epoetin alfa.
2. A client has been taking Sertraline for the past 2 days. Which of the following assessment findings should alert the nurse to the possibility that the client is developing Serotonin syndrome?
- A. Bruising
- B. Fever
- C. Abdominal pain
- D. Rash
Correct answer: B
Rationale: The correct answer is B: Fever. Fever is a key symptom of serotonin syndrome, a potentially life-threatening condition that can occur with the use of serotonergic medications like Sertraline. Serotonin syndrome is characterized by a combination of symptoms, including fever, agitation, rapid heartbeat, sweating, shivering, tremors, and in severe cases, it can lead to seizures, coma, and even death. Bruising (Choice A), abdominal pain (Choice C), and rash (Choice D) are not typically associated with serotonin syndrome. Therefore, the nurse should be vigilant in monitoring for fever as an early sign of serotonin syndrome in clients taking Sertraline.
3. A healthcare professional is caring for a client who is receiving treatment with carboplatin. Which of the following findings should the healthcare professional monitor?
- A. Hyperglycemia
- B. Ototoxicity
- C. Hypertension
- D. Bradycardia
Correct answer: B
Rationale: The healthcare professional should monitor the client for ototoxicity when receiving carboplatin. Ototoxicity is a known serious adverse effect associated with this medication, characterized by damage to the inner ear structures leading to hearing loss or balance issues. Monitoring for hearing changes and balance problems is crucial to detect ototoxicity early and prevent further complications. Hyperglycemia, hypertension, and bradycardia are not typically associated with carboplatin therapy.
4. A healthcare professional in a provider's office is reviewing the medical record of a client who is pregnant and is at her first prenatal visit. Which of the following immunizations may the healthcare professional administer safely to this client?
- A. Varicella vaccine
- B. Rubella vaccine
- C. Inactivated influenza vaccine
- D. Measles vaccine
Correct answer: C
Rationale: During pregnancy, it is safe for women to receive the inactivated influenza vaccine, which is recommended by healthcare providers to protect pregnant individuals from influenza. Vaccination with inactivated influenza vaccine during pregnancy not only provides protection to the pregnant individual but also confers passive immunity to the newborn during the vulnerable early months of life. The Varicella, Rubella, and Measles vaccines are live vaccines and are contraindicated during pregnancy due to the theoretical risk of transmission of the live virus to the fetus, which could potentially cause harm.
5. When taking Digoxin, low levels of what can cause toxicity?
- A. Potassium
- B. Calcium
- C. Sodium
- D. Magnesium
Correct answer: A
Rationale: Low potassium levels can lead to Digoxin toxicity. Digoxin competes with potassium for binding sites on the sodium-potassium pump. When potassium levels are low, there is an increased risk of Digoxin binding and toxicity. Choice B (Calcium) is incorrect because low calcium levels are not directly linked to Digoxin toxicity. Choice C (Sodium) is incorrect as low sodium levels do not cause Digoxin toxicity. Choice D (Magnesium) is incorrect as low magnesium levels do not contribute to Digoxin toxicity.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access